UNIV OF CA SAN FRAN
PharmaUNIV OF CA SAN FRAN is a pharmaceutical company focused on Oncology. Key products include GALLIUM GA 68 GOZETOTIDE.
UNIV OF CA SAN FRAN's Key Drugs
UNIV OF CA SAN FRAN's core commercial portfolio centers on GALLIUM GA 68 GOZETOTIDE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
UNIV OF CA SAN FRAN's Recent FDA Approvals
New NDA/BLA approvals for UNIV OF CA SAN FRAN over the last two years — novel drugs only, excluding generics and label supplements.
UNIV OF CA SAN FRAN's Therapeutic Areas
UNIV OF CA SAN FRAN's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UNIV OF CA SAN FRAN's Top Competitors
UNIV OF CA SAN FRAN's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UNIV OF CA SAN FRAN Pipeline Snapshot
Active clinical trials for UNIV OF CA SAN FRAN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GALLIUM GA 68 GOZETOTIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-12-01
- Latest
- 2022-06-16
- Applications
- 1